scholarly journals De-Escalating Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1787
Author(s):  
Panagiota Economopoulou ◽  
Ioannis Kotsantis ◽  
Amanda Psyrri

HPV-related head and neck squamous cell carcinoma (HNSCC) has emerged as a diverse clinical and biological disease entity, mainly in young patients with oropharyngeal tumors who are nonsmokers and nondrinkers. Indeed, during the past few years, the pendulum has shifted towards a new epidemiological reality, the “HPV pandemic”, where the majority of oropharyngeal squamous cell carcinomas (OPSCCs) are attributed to HPV. The oncogenic potential of the virus is associated to its capacity of integrating oncogenes E6 and E7 into the host cell, leading to the inactivation of several tumor suppressor genes, such as Rb. HPV status can affect prognosis in OPSCC, but its role as a predictive biomarker remains to be elucidated. Given the favorable prognosis associated with HPV-positive disease, the concept of de-escalation treatment strategies has been developed with the primary intent being the reduction of treatment-related long-term toxicities. In this review, we aim to depict current data regarding treatment de-escalation in HPV-associated OPSCC and discuss ongoing clinical trials.

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 500 ◽  
Author(s):  
Katherine C. Wai ◽  
Madeleine P. Strohl ◽  
Annemieke van Zante ◽  
Patrick K. Ha

The incidence of human papillomavirus (HPV)-related head and neck squamous cell carcinoma continues to increase. Accurate diagnosis of the HPV status of a tumor is vital, as HPV+ versus HPV– tumors represent two unique biological and clinical entities with different treatment strategies. High-risk HPV subtypes encode oncoproteins E6 and E7 that disrupt cellular senescence and ultimately drive tumorigenesis. Current methods for detection of HPV take advantage of this established oncogenic pathway and detect HPV at various biological stages. This review article provides an overview of the existing technologies employed for the detection of HPV and their current or potential future role in management and prognostication.


2018 ◽  
Vol 18 (3) ◽  
pp. 182-191 ◽  
Author(s):  
Linda L. Eastham ◽  
Candace M. Howard ◽  
Premalatha Balachandran ◽  
David S. Pasco ◽  
Pier Paolo Claudio

Enthusiasm for the use of dietary bioactive compounds as chemopreventive agents and adjuvants for current therapies has increased laboratory research conducted on several types of cancers including Head and Neck Squamous Cell Carcinoma (HNSCC). The green chemoprevention movement is a modern approach to highlight healthy lifestyle changes that aim to decrease the incidence of HNSCC. A healthy diet can be an effective way to prevent the development of oral cancers. Discovery of the naturally occurring plant based compounds called phytochemicals has facilitated the development of new treatment strategies for patients that are at risk for, or have developed HNSCC. Many of these compounds have been shown to elicit very potent anti-carcinogenic properties. While there are many compounds that have been studied, the compounds from two specific categories of phytochemicals, phenolics (resveratrol, EGCG, curcumin, quercetin, and honokiol) and glucosinolates (sulforaphane, PEITC and BITC), are emerging as potent and effective inhibitors of oral carcinogenesis. These compounds have been shown to inhibit HNSCC growth through a variety of mechanisms. Research has demonstrated that these compounds can regulate cancer cell proliferation through the regulation of multiple cell signaling pathways. They can impede cell cycle progression, induce differentiation and apoptosis, prevent angiogenesis, and inhibit cancer cell invasive and metastatic properties. They can protect normal cells during treatment and reduce the damage caused by chemotherapy and radiotherapy. This review aims to provide an overview of some of the most effective phytochemicals that have the potential to successfully prevent and treat head and neck squamous cell carcinoma.


2015 ◽  
Vol 8 (4) ◽  
pp. 287-295 ◽  
Author(s):  
Eleni M. Rettig ◽  
Christine H. Chung ◽  
Justin A. Bishop ◽  
Jason D. Howard ◽  
Rajni Sharma ◽  
...  

2011 ◽  
Vol 130 (8) ◽  
pp. 1806-1812 ◽  
Author(s):  
H.S. van Monsjou ◽  
M.L.F. van Velthuysen ◽  
M.W.M. van den Brekel ◽  
E.S. Jordanova ◽  
C.J.M. Melief ◽  
...  

1990 ◽  
Vol 36 (5) ◽  
pp. 1296-1307
Author(s):  
Mitsuhiro NAKAZAWA ◽  
Motohiro TSUJINO ◽  
Tomoji MORIYAMA ◽  
Tetsurou SUMI ◽  
Yoshihide MORI ◽  
...  

2013 ◽  
Vol 19 (19) ◽  
pp. 5444-5455 ◽  
Author(s):  
Roberto A. Lleras ◽  
Richard V. Smith ◽  
Leslie R. Adrien ◽  
Nicolas F. Schlecht ◽  
Robert D. Burk ◽  
...  

2021 ◽  
Author(s):  
Hajime Ishinaga ◽  
Yoshinaga Okugawa ◽  
Bo Hou ◽  
Feng He ◽  
Chengzeng Yin ◽  
...  

Abstract ObjectiveThis study aimed to clarify whether circulating miR-21 represents a predictive biomarker in patients with head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy, and to investigate the effect of miR-21 inhibitor for chemoradiation in human SCC cells.MethodsPlasma samples were obtained from 22 patients with HNSCC and 25 non-cancer volunteers. Plasma miR-21 expression was measured using real-time quantitative reverse transcription polymerase chain reaction. The effects of miR-21 inhibitor in human SCC cells were investigated by performing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, and Western blot analysis.ResultsPlasma miR-21 expression was higher in HNSCC patients than in control patients (p< 0.001). Seven patients with recurrence showed significantly higher plasma miR-21 than the 15 patients without recurrence. Moreover, miR-21 inhibition significantly enhanced cisplatin- or radiation-induced apoptosis. Western blot analysis suggested the programmed cell death 4 (PDCD4) protein as a potential target of miR-21 in relation to apoptosis. Adding miR-21 inhibition to radiation or cisplatin treatment provided clear and potent suppression of tumor cell proliferation.ConclusionThis study provides new insights into the role of miR-21 as a predictive biomarker for HNSCC treated with chemoradiotherapy, and suggests a potential target to improve the effects of chemoradiotherapy against HNSCC.


Sign in / Sign up

Export Citation Format

Share Document